Stock 2552 HUA MEDICINE (SHANGHAI) LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Hua Medicine (Shanghai) Ltd.

Equities

2552

KYG4644K1022

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:22 29/04/2024 pm IST 		5-day change 1st Jan Change
1.64 HKD +1.23% Intraday chart for Hua Medicine (Shanghai) Ltd. +9.33% -16.75%
28/03 Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024
Hua Medicine Intends to Conduct Trials of Diabetes Drug in US
Hua Medicine Submits Investigational New Drug Application with the U.S. Food and Drug Administration for the 2Nd Generation Glucokinase Allosteric Activator
China Includes Hua Medicine's Type 2 Diabetes Medication in Drug Reimbursement List
Hua Medicine's Unit Receives 800 Million Yuan for Development of Diabetes Drug
Hua Medicine Ltd. Announces Board and Committee Changes
Hua Medicine Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Hua Medicine Signs Distribution Agreement with Digital Healthcare Platform
Hua Medicine Ltd. Announces Resignation of Mr. Junling Liu as Independent Non-Executive Director and Change in Composition of the Board Committees
Hua Medicine Shrinks Loss in 2022 as Revenue Witnesses a Boost
Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Hua Medicine Makes 49 Million Yuan of HuaTangNing Sales Since Launch
Hua Medicine Receives 400 Million Yuan in Milestone Payments for Diabetes Treatment
Hua Medicine Ltd. Announces Directorate and Committee Changes
Hua Medicine Announces Demise of Walter Teh-Ming Kwauk, an Independent Non-Executive Director
Hua Medicine Unit Buys 100% Stake in Diabetes Drug Research Company
China OKs Hua Medicine's New Drug Application for Type 2 Diabetes Treatment; Shares slipped 11%
Hua Medicine Announces Approval of NDA of Huatangning, Innovative First-In-Class GKA Potential Inside Information
Hua Medicine Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2552 Stock
  4. News Hua Medicine (Shanghai) Ltd.
  5. Other languages